Stock A002620 JEIL PHARMA HOLDINGS INC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jeil Pharma Holdings Inc

Equities

A002620

KR7002620003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
10,670 KRW -1.57% Intraday chart for Jeil Pharma Holdings Inc -3.87% -9.35%
2023 Jeil Pharma Holdings Inc Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2022 Jeil Pharma Holdings Inc's Equity Buyback Plan Extended till October 2, 2042. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 396,059 260,969 325,444 245,618 236,407 180,683
Enterprise Value (EV) 1 466,703 353,452 445,276 313,466 345,621 335,694
P/E ratio 18.9 x -2.88 x 28.5 x -70.5 x -3.17 x -11.1 x
Yield 0.27% 0.41% 0.33% 0.41% 0.32% 0.42%
Capitalization / Revenue 2.77 x 0.36 x 0.43 x 0.32 x 0.3 x 0.22 x
EV / Revenue 3.27 x 0.48 x 0.58 x 0.41 x 0.44 x 0.42 x
EV / EBITDA 37 x 21.6 x 14.5 x 37,729 x 103 x 10 x
EV / FCF -3.34 x 123 x -16.7 x 39.9 x -17.1 x -16.9 x
FCF Yield -30% 0.81% -5.99% 2.51% -5.85% -5.92%
Price to Book 0.81 x 0.66 x 0.8 x 0.6 x 0.7 x 0.57 x
Nbr of stocks (in thousands) 15,351 15,351 15,351 15,351 15,351 15,351
Reference price 2 25,800 17,000 21,200 16,000 15,400 11,770
Announcement Date 13/03/19 17/03/20 15/03/21 15/03/22 16/03/23 12/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 142,736 731,140 761,997 762,568 792,965 804,043
EBITDA 1 12,608 16,389 30,654 8.308 3,357 33,476
EBIT 1 10,949 8,607 22,003 -8,975 -7,548 20,920
Operating Margin 7.67% 1.18% 2.89% -1.18% -0.95% 2.6%
Earnings before Tax (EBT) 1 9,788 -82,600 30,822 -6,129 -83,861 -13,982
Net income 1 7,070 -90,661 11,431 -3,482 -74,556 -16,250
Net margin 4.95% -12.4% 1.5% -0.46% -9.4% -2.02%
EPS 2 1,363 -5,906 744.6 -227.0 -4,857 -1,059
Free Cash Flow 1 -139,801 2,880 -26,675 7,866 -20,230 -19,889
FCF margin -97.94% 0.39% -3.5% 1.03% -2.55% -2.47%
FCF Conversion (EBITDA) - 17.57% - 94,673.82% - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 70.00 70.00 70.00 65.00 50.00 50.00
Announcement Date 13/03/19 17/03/20 15/03/21 15/03/22 16/03/23 12/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 70,644 92,483 119,832 67,848 109,213 155,012
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 5.603 x 5.643 x 3.909 x 8,166 x 32.53 x 4.63 x
Free Cash Flow 1 -139,801 2,880 -26,675 7,866 -20,230 -19,889
ROE (net income / shareholders' equity) 1.83% -17.9% 3.05% -2.58% -18.1% -3.22%
ROA (Net income/ Total Assets) 1.18% 0.61% 1.59% -0.63% -0.54% 1.5%
Assets 1 601,392 -14,886,805 720,162 552,501 13,894,099 -1,084,763
Book Value Per Share 2 31,941 25,632 26,542 26,821 22,003 20,810
Cash Flow per Share 2 2,677 1,383 1,315 1,862 2,264 2,413
Capex 1 50,199 37,686 9,811 23,688 15,462 6,223
Capex / Sales 35.17% 5.15% 1.29% 3.11% 1.95% 0.77%
Announcement Date 13/03/19 17/03/20 15/03/21 15/03/22 16/03/23 12/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
JEIL PHARMA HOLDINGS INC Stock Jeil Pharma Holdings Inc
-9.35% 120M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+21.28% 44.4B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+24.60% 23.03B
SANDOZ GROUP AG Stock Sandoz Group AG
+17.81% 15.14B
CIPLA LIMITED Stock Cipla Limited
+12.87% 13.12B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+44.67% 11.85B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.33% 6.99B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.22% 5.52B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A002620 Stock
  4. Financials Jeil Pharma Holdings Inc